Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > What is status of C-60 project?
View:
Post by lscfa on Feb 12, 2021 10:56am

What is status of C-60 project?

C-60 R&D Project
Voyageur is working on replicating the process to prove the claims that C-60 can be extracted by rock. We have engaged an independent lab, a large technical institute and a University to process and evaluate samples. We will publish results upon completion of testing which may take between 2-3 months.
Upon successful C-60 testing results, a Joint Venture will be formed between several of the parties involved in the development of the C60 project. Voyageur will have first rights to all C-60 produced for the health care markets.
This will then lead into creating a pipeline of C-60 drug products focused on:
1. Contrast media drug carrier for Fe, I, Gd and potentially Ba.
2. Anti Virus drug development, including Corona Virus / COVID-19 and influenzas immunisation
drugs
3. Natural health Supplements
Comment by WarrantOfficer on Feb 12, 2021 2:30pm
Iscfa: Where did you get your C60 R&D Project Info? Cheers!
Comment by lscfa on Feb 12, 2021 2:44pm
This is from the MD&A filed July 23/20.    
Comment by postie1 on Feb 12, 2021 2:54pm
Have never heard a peep about it since they revamped everything. But with  VM one never knows when news will hit. Since that is newer technology that is being worked on, I do not expect the time frame to be precise. I value VM based on Barite and Iodine but if that stuff works out who knows just where the share price could end up. The potential for C60 is huge.
Comment by WarrantOfficer on Feb 12, 2021 3:10pm
This is from A PR dated 18 Nov 2020: The Company issued a news release on May 11, 2020 that provided an update on the Company's C-60 - Fullerene project (the "Project"). The Company would like to clarify that the information provided in that news release was preliminary and a significant amount of due diligence and work is required to progress the Project or draw any conclusions ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1